Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Overall Survival Results from the RUBY Trial
Resources for Healthcare Professionals
Want to know more about Jemperli dostarlimab
Get in touch with your local GSK Ireland Team today to learn more.
Adverse event reporting information can be found at the bottom of this page.
JEMPERLI Indication
- JEMPERLI is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.
- JEMPERLI is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability‑high (MSI‑H) recurrent or advanced EC that has progressed on or following prior treatment with a platinum‑containing regimen.
POM. Further information is available from GlaxoSmithKline (Ireland) Ltd
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via online form https://gsk.public.reportum.com/.
© GSK Group of Companies or its licensor. Trademarks are owned by or licensed to the GSK group of companies.
PM-IE-DST-WCNT-240004 | April 2026
